Trius Therapeutics

Piper Jaffray, which raised its PT on shares of Trius Therapeutics, Inc. (NASDAQ: TSRX), is providing color on the stock. “Following a recent successful offering, we estimate Trius now holds pro forma cash of $65 million,” Piper Jaffray writes. “This strengthened balance sheet enables Trius to...

Piper Jaffray has raised the price target on Trius Therapeutics (NASDAQ: TSRX) from $7 to $11 and maintains its Overweight rating.

Global Hunter is out with its report today on Trius Therapeutics (NASDAQ: TSRX), initiating TSRX at Buy. In a note to clients, Global Hunter writes, "TSRX is an emerging, under-covered name in the antibiotics space. We believe the company's lead program, torezolid phosphate, represents a...

Bank of America has initiated coverage on Trius Therapeutics (NASDAQ: TSRX) with a Buy rating and $11 price objective.

Citi has reported on the fourth quarter results for Trius Therapeutics (NASDAQ: TSRX). According to the report, "Trius had an uneventful Q4 with revenues of $2.5M vs. Citi $1.94M. Revenues increased due to the initiation of work on the second federal research contract from the Defense Threat...